Dual PPARα/δ agonist elafibranor (GFT505) shows positive effects in glucose and lipid metabolism and reduces inflammation in NASH patients in a phase 2 clinical trial. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.